Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study
Objectives To compare the survival of first-and second-generation tyrosine kinase inhibitors
(TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung …
(TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung …
Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology …
B Bilgin, MAN Sendur, S Yucel, E Celik… - Journal of Cancer …, 2021 - Springer
Background The new second-generation tyrosine kinase inhibitors (TKIs) have superior
survival outcome and worse toxicity profile when compared with first-generation TKIs …
survival outcome and worse toxicity profile when compared with first-generation TKIs …
Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations
P Krawczyk, DM Kowalski, R Ramlau… - Oncology …, 2017 - spandidos-publications.com
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are routinely used
to treat non-small cell lung cancer (NSCLC) in patients with common activating mutations of …
to treat non-small cell lung cancer (NSCLC) in patients with common activating mutations of …
Efficacy of EGFR-Tyrosine Kinase Inhibitors for advanced non-small cell lung cancer patients harboring rare EGFR mutations of exon 18 E709X
Y Hao, M Xu, H Zhou, J Si, Y Fang, C Xu, Z Song - Medical Oncology, 2022 - Springer
EGFR-tyrosine kinase inhibitors (TKIs) show efficacy against lung cancer, and afatinib has
been used as a standard therapy for patients with non-small cell lung cancer (NSCLC) with …
been used as a standard therapy for patients with non-small cell lung cancer (NSCLC) with …
Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations
I Tanaka, M Morise, Y Kodama, A Matsui… - Lung …, 2019 - lungcancerjournal.info
Uncommon epidermal growth factor receptor (EGFR) mutations in non-small cell lung
cancer (NSCLC) are a heterogeneous group of genetic alterations that produce variable …
cancer (NSCLC) are a heterogeneous group of genetic alterations that produce variable …
EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes
H Xu, G Yang, W Li, J Li, X Hao, P Xing, Y Yang… - Frontiers in …, 2021 - frontiersin.org
Background Approximately 3–5% of patients with epidermal growth factor receptor (EGFR)
mutation-positive non-small cell lung cancer (NSCLC) harbor exon 18 mutations. The …
mutation-positive non-small cell lung cancer (NSCLC) harbor exon 18 mutations. The …
159P Clinical activity of afatinib in a cohort of patients with lung adenocarcinoma harbouring uncommon EGFR mutations: A Spanish retrospective multicentre study
Background: Uncommon EGFR mutations (u-EGFRm) in exons 18–21 account for 12–15%
of overall EGFR mutations in non-small cell lung cancer (NSCLC). Afatinib has shown …
of overall EGFR mutations in non-small cell lung cancer (NSCLC). Afatinib has shown …
EGFR exon 18 mutations in lung cancer: molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first-or third-generation TKIs
Y Kobayashi, Y Togashi, Y Yatabe, H Mizuuchi… - Clinical cancer …, 2015 - AACR
Purpose: Lung cancers harboring common EGFR mutations respond to EGFR tyrosine
kinase inhibitors (TKI), whereas exon 20 insertions (Ins20) are resistant to them. However …
kinase inhibitors (TKI), whereas exon 20 insertions (Ins20) are resistant to them. However …
Effectiveness of EGFR tyrosine kinase inhibitors in advanced non‐small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study
M Kanazu, M Mori, M Kimura, K Nishino… - Thoracic …, 2021 - Wiley Online Library
Background Epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) therapy
is the standard treatment for advanced non‐small cell lung cancer (NSCLC) harboring …
is the standard treatment for advanced non‐small cell lung cancer (NSCLC) harboring …
Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations
D Chen, Z Song, G Cheng - OncoTargets and therapy, 2016 - Taylor & Francis
Purpose Subsets of non-small-cell lung cancer patients with epidermal growth factor
receptor (EGFR) mutations carry uncommon subtypes. We evaluated the efficacy of first …
receptor (EGFR) mutations carry uncommon subtypes. We evaluated the efficacy of first …